I-Corps: An enzymatic method for eradicating biofilm and multidrug resistant bacterial infections

这项技术是基于一项研究结果，即酶治疗可以防止生物膜的形成，并使多重耐药病原体（包括革兰氏阴性和阳性细菌）对抗生素治疗重新敏感。体外实验和动物模型实验均已成功完成，并证明了该技术的有效性。该酶可能单独使用或作为辅助剂，以提高现有和已批准的抗生素的疗效，以根除在许多情况下被认为是不可治疗的疾病的多药耐药性感染。生物膜相关感染和多药耐药的发生是一个严重的世界性公共卫生问题。仅在美国，每年就有大约200万人在医院感染细菌，导致99000人死亡。最初的目标应用是伤口感染和手术部位感染的局部应用。酶和抗生素联合治疗可以改善临床对皮肉伤口和细菌感染的治疗方式。该技术还可应用于院内肺炎、菌血症和败血症、囊性纤维化感染、导管相关性菌尿等，特别是在最后一线抗生素无效的情况下。

This technology is based on research findings that an enzyme treatment can prevent biofilm formation and re-sensitize multidrug resistant pathogens (including both gram-negative and positive bacteria) to antibiotic treatment. Both in vitro and animal model experiments have been successfully completed and demonstrated the efficacy of this technology. The enzyme can potentially be used to alone or as an adjuvant to improve the efficacy of existing and approved antibiotics to eradicate multidrug resistance infections, which in many cases are considered to be non-treatable diseases. Biofilm-related infections and the occurrence of multidrug resistance is a serious worldwide public health problem. In the US alone, roughly 2 million people acquire bacterial infections in the hospital which leads to 99,000 deaths annually. The initial target application is the topical application for wound infections and surgical site infections. Combinatorial the enzyme and antibiotic treatment could improve and the way flesh wounds and bacterial infections are treated in the clinic. The technology can also be applied to nosocomial pneumonia, bacteremia and sepsis, Infections in cystic fibrosis, catheter-associated bacteriuria, etc. especially when the last line of antibiotics is not effective.